



## **ARCXIS BIOTECHNOLOGIES® SECURES SERIES B FINANCING**

**January 30, 2009**

Arcxis Biotechnologies, a privately held biomedical device firm, announced today that it has completed the first close of its Series B round. Claremont Creek Ventures, who led the round, was joined by Kaiser Permanente Ventures and Alafi Capital. These funds will enable Arcxis to accelerate development, testing, and commercialization of their innovative nucleic acid sample preparation platform and their next generation sample to answer clinical molecular diagnostic platform.

By rapidly isolating, identifying and characterizing genes and proteins, Arcxis Biotechnologies' products will enable faster, more accurate and more economical diagnosis of infectious diseases and other conditions marked by genetic and proteomic changes, such as cancer. The company's products may also be used for environmental and epidemiological applications.

"Claremont Creek Ventures is excited about the ongoing investment in Arcxis which will help the company bring this important new technology to clinical molecular laboratories around the world." "Arcxis's expertise has enabled the development of one of the most promising clinical molecular diagnostic platforms in the industry," stated John Steuart, Managing Director.

"This 2<sup>nd</sup> round of institutional investment enables us to initiate the commercial development programs in our strategic plan," said Chris Meda, president and chief executive officer of Arcxis. "Given the current financial market, it is indeed exciting to have the confidence of our investors."

### **About Kaiser Permanente Ventures:**

Kaiser Permanente Ventures, the corporate venture capital arm of Kaiser Permanente, makes investments in medical devices, healthcare services and information technology companies. Kaiser Permanente Ventures is dedicated to partnering with entrepreneurial companies to build innovative and enduring businesses that advance the quality and affordability of health care. Since its inception in 1997, Kaiser Permanente Ventures has invested in more than 25 venture-capital backed companies at all stages of development, and contributed organizational expertise, time and resources to the success of these companies. For additional information please visit [www.kpventures.com](http://www.kpventures.com).